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Summary
 
Objectives
 
To examine quality of life (QoL) measured by a
utility-weighted index in GH-deﬁcient adults on GH replacement
and analyse the impact of demographic and clinical characteristics
on changes in utilities during treatment.
 
Design
 
Utilities for items in the QoL-Assessment of Growth
Hormone Deﬁciency in Adults (QoL-AGHDA
 
utility
 
) were estimated
based on data obtained from the general population in England and
Wales (E&W). These estimates were used to calculate QoL changes
in GH-treated patients and compare these with normative
population values.
 
Patients
 
A total of 894 KIMS patients (53% women) from E&W
were followed for 1 to 6 years.
 
Measurements
 
QoL-AGHDA
 
utility
 
 at baseline and at the last
reported visit, total QoL-AGHDA
 
utility
 
 gain and QoL-AGHDA
 
utility
 
gain per year of follow-up.
 
Results
 
QoL-AGHDA
 
utility
 
 in patients before GH treatment differed
from the expected population values [0·67  (SD  0·174) 
 
vs.
 
 0·85
(SD 0·038), 
 
P
 
 < 0·0001], constituting a mean deﬁcit of –0·19 (SD 0·168).
There was a difference in the mean QoL-AGHDA
 
utility
 
 deﬁcit for men
[–0·16 (SD 0·170)] and women [–0·21 (SD 0·162)] (
 
P < 
 
0·001). The
main improvement occurred during the ﬁrst year of treatment
[reduction of a deﬁcit to –0·07 (SD 0·163) (
 
P < 
 
0·001) in the total
cohort]; however, patients’ utilities remained lower than those
recorded for the general population during subsequent follow-up
(
 
P < 
 
0·001). Despite an observed impact of age, primary aetiology,
disease onset and comorbidities on QoL-AGHDA
 
utility
 
,
 
 
 
all patients
showed a similar beneﬁcial response to treatment.
 
Conclusions
 
QoL-AGHDA
 
utility
 
 efﬁciently monitors treatment
effects in patients with GHD. The study conﬁrmed the QoL-
AGHDA
 
utility
 
 deﬁcit before treatment and a similar QoL-AGHDA
 
utility
 
gain observed after commencement of GH replacement in all patients.
(Received 11 April 2007; returned for revision 18 May 2007; ﬁnally 
 
revised 15 June 2007; accepted 25 June 2007)
 
Introduction
 
Quality of life (QoL) has emerged as an important construct that
has found numerous applications across health care-related ﬁelds,
ranging from randomized controlled trials, as well as pharmaco-
economic evaluation, through to daily clinical practice. Each of these
applications imposes different requirements on the QoL measures.
Pharmacoeconomic evaluation often requires that health status is
expressed as a single summary score (a health status index) that is
capable of identifying and quantifying differences across diseases as
well as aggregate changes in health status over time in patients.
 
1
 
By contrast, clinical applications usually require a measure that
captures speciﬁc changes within a certain disease, in patient popu-
lations (in clinical trials) and in individual patients (in daily clinical
practice).
 
2
 
 Economic applications impose further requirements
when the effects of health care are assessed by cost–utility analysis.
Here it is expected that such effects are expressed in terms of quality-
adjusted life years (QALYs). This unit of measure combines informa-
tion on length of life (quantity) and quality of life, where the latter
is measured on a scale that has values of 1 and 0, respectively, for
full health and death (Fig. 1). The unit QALY is therefore deﬁned as
1 year of life with full health. When a QoL index is used to calculate
QALY beneﬁts, health economists also require that the value of
health should be estimated in terms of utility weights using prefer-
ence measurement techniques such as Time Trade-Off (TTO) or
Standard Gamble (SG). In summary, economists make different
requirements of QoL measurement compared with clinicians,
principally as a result of their different information needs.
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As impairment in QoL is a key clinical feature of growth hormone
deﬁciency (GHD) in adults,
 
3,4
 
 these theoretical aspects of QoL
assessment are becoming a matter of signiﬁcance for all stakeholders.
Disease-orientated measures such as the QoL-Assessment of GHD
in Adults (QoL-AGHDA)
 
5
 
 and the Questions on Life Satisfaction
Hypopituitarism Module (QLS-H)
 
6
 
 have been developed for use by
clinicians, while health economists continue to rely on preference-
based approaches to measure QoL in this group of patients.
 
7,8
 
The interrelationship between preference-based QoL assessments
and results derived by disease-sensitive instruments is of interest to
researchers, mainly because of its numerous practical implications.
 
9–11
 
However, in endocrinology such research seems to have been
relatively neglected and as far as we are aware has not been under-
taken in the ﬁeld of adult GHD. Our study aimed to bridge the gap
between clinicians and health economists by addressing the issue of
consistency between QoL measures as used in clinical practice and
QALYs. We also examined the QoL deﬁcit, measured by a utility-
weighted index (utility) in GH-treated hypopituitary adults with
GHD in relation to the general population, and the impact of
demographic and clinical characteristics on the change in utilities
during GH treatment.
 
Methods and subjects
 
Study design
 
The study consisted of two parts, the ﬁrst of which estimated utilities
for the QoL-AGHDA based on data obtained from a survey of the
general population in England and Wales (E&W). The second part
used utility-weighted QoL-AGHDA data to calculate QoL changes
in patients during treatment in relation to normative population
values, also examining the impact of demographic and patients’
clinical characteristics.
 
General population – deriving utilities
 
EQ-5D,
 
12
 
 a generic measure of QoL developed by the EuroQoL
group, deﬁnes a total of 243 health states for each of which there is
a corresponding score based on values obtained from the UK general
population, using TTO methods.
 
13
 
 Based on these data a set of utilities
for all health states described by the EQ-5D has been estimated.
The QoL-AGHDA consists of 25 items that evoke yes/no answers
to speciﬁc problems. A total score is produced by summing across
all items; a high QoL-AGHDA score denotes a poor QoL.
A questionnaire package containing EQ-5D and QoL-AGHDA
was sent out to 1190 individuals from a general population in E&W
 
14
 
(response rate 84%). For the purpose of this study, responses from
921 individuals (56% women) who returned complete EQ-5D and
QoL-AGHDA questionnaires were included. The mean age (years)
of the participants was 53·8 (SD 14·28): 56·3 (SD 14·05) for men and
51·7 (SD 14·16) for women.
A regression model was used to estimate utility weights for
QoL-AGHDA items. The TTO-weighted EQ-5D
 
index 
 
was used
 
 
 
as
the dependent variable and QoL-AGHDA item responses were
entered as independent dummy variables together with age as a
covariate.
QoL-AGHDA
 
utility
 
 
 
→
 
 ED-5D
 
index
 
 
= 
 
b
 
0
 
 + (
 
c
 
 
 
×
 
 age) + 
 
Σ 
 
b
 
i
 
 
 
×
 
 
 
x
 
i
 
 + 
 
e
 
i
 
(1)
where 
 
x
 
i
 
 (
 
i
 
 = 1–25) correspond to the 25 dichotomous items (coded
as 0 = no or 1 = yes) that are summed to form the QoL-AGHDA
score, 
 
b
 
i
 
 are the regression coefﬁcient estimates, and 
 
e
 
i
 
 correspond
to error terms.
The model demonstrated an adjusted 
 
R
 
2
 
 of 0·42. Each regression
coefﬁcient, 
 
b
 
i
 
, represents the utility weight for the corresponding
QoL-AGHDA item and when aggregated across all 25 items, this
yields an estimate of the utility-weighted QoL-AGHDA, referred to
here as QoL-AGHDA
 
utility
 
.
 
Adult hypopituitary patients
 
The patients were retrieved from the KIMS (Pﬁzer International
Metabolic Database).
 
15
 
 Data were collected on specially designed
case report forms and monitored by study monitors. Each KIMS
centre obtained approval from its local ethics committee and patients
gave informed consent, either verbally or in writing, depending on
the local legal requirements.
Model (1) was used to transform patients’ QoL-AGHDA scores
into QoL-AGHDA
 
utility
 
. Additionally, QoL-AGHDA
 
utility
 
 was
correlated against Psychological General Well-Being
 
16
 
 (PGWB)
scores. The PGWB is a 22-item questionnaire with higher values
indicating more satisfactory feelings. The total score ranges from
22 to 132 (with higher scores representing better psychological
well-being).
 
Calculating QALYs
 
Patients had been followed in the KIMS database for a varying
number of years. The total QoL-AGHDA
 
utility
 
 for each patient was
calculated using the trapezoid formula as follows (Fig. 1).
Fig. 1 The area under the curve represents QALYs measured by QoL-
AGHDAutility during 6 years of treatment, where A depicts general population 
values, B gain during GH replacement, and C values for patients with 
GHD without treatment. The value 1 on the y-axis stands for full health, 
and 0 for death. 
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Σ
 
(
 
u
 
i
 
–1
 
 – 2
 
u
 
0
 
 + 
 
u
 
i
 
)/2  (
 
i
 
 = 1, 
 
t
 
) (2)
where 
 
t
 
 = total duration of patient follow-up in KIMS, and 
 
u
 
i
 
 =
QoL-AGHDA
 
utility
 
 at year 
 
i
 
.
The average change in QALYs over the entire time period was
also computed as gain per year. Missing observations between
years were substituted using the last observation carried forward
(LOCF) technique. The calculation was performed conservatively,
assuming that an untreated patient would stay in the same QoL stage
as baseline observation. The patient QALY deﬁcit was calculated as
the difference between the QoL-AGHDA
 
utility 
 
observed in patients
and the corresponding value computed for age/gender-matched
individuals in the general population sample.
A high QoL-AGHDA
 
utility 
 
score
 
 
 
denotes better QoL assessment,
which is contrary to the interpretation of a QoL-AGHDA raw score,
where a high value indicates poor QoL.
 
Patients subgroups
 
Finally, QoL-AGHDA
 
utility 
 
at baseline and following GH treatment
was evaluated with respect to age, gender, primary aetiology,
onset of pituitary disease (childhood 
 
vs.
 
 adulthood), extent of
hypopituitarism and medical history.
 
Statistics
 
Parametric statistics were applied when analysing differences
between subgroups.
Descriptive statistics are given as mean (SD). One-sample and
independent samples 
 
t
 
-tests and one-way analysis of variance
(ANOVA) were used, as well as Pearson correlation analysis. Multiple
forward regression analysis was also applied to control for the
inﬂuence of age and gender on QALYs. A 
 
P
 
-value less than 0·05 was
considered statistically signiﬁcant.
IGF-I concentrations are described as SD scores. SD scores are
calculated as [observed serum IGF-I level – population mean serum
IGF-I level (standardized for age and gender)]/population
standardized standard deviation.
 
Results
 
The mean observed EQ-5D
 
index
 
 in the general population
[0·83 (SD 0·214) in men and 0·81 (SD 0·228) in women] reﬂected
closely the estimated QoL-AGHDA
 
utility
 
 [0·83 (SD 0·127) in men and
0·83 (SD 0·141) in women].
 
Patient characteristics
 
The patient cohort consisted of 894 participants (53% women) from
E&W who were followed up for 1 to 6 years. Mean observation time
was 3·4 (1·74) years. All patients had GHD conﬁrmed by relevant
stimulation tests and were not treated with GH for a minimum of
6 months prior to entry.
The mean age of the patients was 40 (SD 16·5) years at diagnosis
of GHD, and 45  (SD  14·3)  years at entry into KIMS. Men were
slightly older than women at both time points: at diagnosis men were
aged 41 (SD 17·1) and were women 40 (SD 15·9), and at entry into
KIMS men were 45 (SD 14·7) and women were 44 (SD 13·9).
Detailed information about primary aetiology, according to
the KIMS classiﬁcation list,
 
17
 
 is presented in Table 1. Almost 40%
of patients received surgery or irradiation for treatment of their
primary disease. Most of the patients developed their disease during
adulthood; only 21·6% had childhood-onset (CO) GHD. Isolated
GHD was present in 13·2% of patients, GHD plus one or two other
pituitary deﬁcits was present in 16·7% and 17·7% of patients,
respectively. Close to 35% of patients were deﬁcient in GH and three
other pituitary hormones, whereas 17·4% had panhypopituitarism.
Gonadotrophin deﬁciency was present in 68·9% of patients, TSH
in 66·9%, ACTH in 65·2% and antidiuretic hormone (ADH) in
25·3%. All pituitary hormone deﬁcits were routinely replaced.
Fractures were reported in 40%, hypertension in 19%, heart
problems in 12%, asthma and/or allergy in 12%, arthrosis in 10%
and diabetes mellitus in 6% of the KIMS patients. Overall, 57% of
KIMS patients reported one concomitant disease and 20%
more than one.
The mean maintenance GH dose (deﬁned as the dose at the
1-year visit) of 0·44 (SD 0·220) mg/day in female patients resulted
Table 1. QoL-AGHDAutility scores (absolute and change) at baseline and at the last reported visit by primary aetiology for hypopituitarism according to the 
KIMS Classiﬁcation List. Data shown as mean (SD)
N % Baseline visit Last reported Total gain Gain/year
Nonfunctioning pituitary adenoma 201 22·5 0·64 (0·169) 0·76 (0·172) 0·36 (0·537) 0·10 (0·121)
Secreting pituitary adenoma 311 34·8 0·64 (0·165) 0·76 (0·166) 0·36 (0·592) 0·09 (0·124)
Other sellar 64 7·2 0·68 (0·182) 0·78 (0·183) 0·30 (0·498) 0·09 (0·124)
Craniopharyngioma 91 10·2 0·71 (0·172) 0·80 (0·172) 0·31 (0·602) 0·07 (0·123)
Extracellar tumour 55 6·2 0·69 (0·163) 0·76 (0·194) 0·18 (0·379) 0·06 (0·101)
Idiopathic GHD 58 6·5 0·75 (0·171) 0·82 (0·165) 0·28 (0·563) 0·07 (0·119)
Treatment for malignancy outside the cranium 20 2·2 0·72 (0·21) 0·82 (0·174) 0·08 (0·654) 0·07 (0·17)
Other causes of acquired GHD 94 10·5 0·68 (0·179) 0·80 (0·154) 0·24 (0·422) 0·07 (0·118)
Total 894 100·0 0·67 (0·174) 0·77 (0·171) 0·32 (0·549) 0·08 (0·122) 
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in a change in serum IGF-I from a mean SD score of –2·26 (SD 1·782)
to 0·25 (SD 1·496) whereas the lower GH dose [0·37 (0·185) mg/day]
in male patients increased serum IGF-I from a mean SD score of
–1·40 (SD 1·915) to 0·52 (SD 1·507).
 
QoL-AGHDA
 
utility
 
The details of raw QoL-AGHDA scores in patients are presented in
Table 2.
The mean QoL-AGHDA
 
utility
 
 score at baseline was 0·67 (SD 0·172).
Women scored signiﬁcantly lower than men [0·63 (SD 0·166) 
 
vs
 
.
0·70 (SD 0·174), 
 
P
 
 < 0·001], indicating a worse QoL. The total observed
QALY gain was higher for women than men [0·38 (SD 0·602) 
 
vs.
 
0·25 (SD 0·473), 
 
P
 
 < 0·001], as was the mean change in QoL-
AGHDA
 
utility
 
 per year [0·10 (SD 0·129) 
 
vs
 
. 0·07 (SD 0·113), 
 
P
 
 < 0·001].
All within-group changes were signiﬁcant (
 
P < 
 
0·001), as shown
in Table 2.
There were signiﬁcant (
 
P < 
 
0·0001) positive correlations between
PGWB scores at baseline, last observation and change in PGWB
score and corresponding measures of QoL-AGHDA
 
utility
 
 (
 
r
 
 = 0·68,
 
r
 
 = 0·68 and 
 
r
 
 = 0·42, respectively). These highly signiﬁcant
correlations indicate consistency between both measures; that is,
if psychological well-being as measured by PGWB improves,
QoL-AGHDA
 
utility
 
 also shows improvement and vice versa.
 
Comparison of QoL-AGHDA
 
utility
 
 in patients and the 
general population
 
QoL measured by QoL-AGHDA
 
utility
 
 in patients before commence-
ment of GH treatment differed signiﬁcantly from the expected
values calculated from the sample of the general population
[0·67 (SD 0·174) 
 
vs.
 
 0·85 (SD 0·038), 
 
P
 
 < 0·0001], constituting a mean
deﬁcit of –0·19 (SD 0·168). There was also a signiﬁcant difference
in the mean QoL-AGHDA
 
utility
 
 deﬁcit for men [–0·16 (SD 0·170)] and
women  [–0·21 (SD 0·162)]  (
 
P < 
 
0·001). The main improvement
occurred during the ﬁrst year of observation when the QoL-
AGHDA
 
utility
 
 deﬁcit was reduced to –0·07 (SD 0·163) (
 
P < 
 
0·001) in
the total cohort and to –0·07 (SD 0·160) (
 
P < 0·001) in men and
–0·08 (SD 0·170)  (P < 0·001) in women. The difference between
genders disappeared after the ﬁrst year of GH treatment. The same
was true for the deﬁcit at the last reported visit: men –0·07 (SD 0·160)
and women –0·08  (SD  0·170). Despite a dramatic improvement
during the ﬁrst year of observation that was maintained during the
whole follow-up period, patients’ QoL-AGHDAutility remained sig-
niﬁcantly different (P < 0·001) from those reported by the general
population (line A in Fig. 1).
Patient subgroups
In the last step of this study, QoL-AGHDAutility at baseline and
response to GH treatment were evaluated with respect to demo-
graphic and clinical characteristics.
Age. QoL-AGHDAutility was negatively correlated with age both at
baseline (r = –0·23; P < 0·0001) and at the latest reported visit (r =
–0·25;  P  <  0·0001), meaning that QoL-AGHDAutility deteriorated
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with advancing age (Fig.  2). However, the mean total QoL-
AGHDAutility gain and also well as the mean gain per year were similar
through all the age groups (data not shown).
Primary aetiology. There were differences in QoL-AGHDAutility
between aetiology groups at baseline and at the last reported visit.
Patients with GHD due to pituitary adenoma, both nonfunctioning
and secreting, had the lowest QoL-AGHDAutility at both time points
(Table 1). However, the primary cause for GHD had no inﬂuence on
the response to treatment measured by total QoL-AGHDAutility gain
and mean gain per year.
Previous treatment. Neither previous surgery nor irradiation had an
impact on QoL-AGHDAutility at any time point, and did not inﬂuence
response to GH (data not shown).
Disease onset. QoL-AGHDAutility scores were higher in patients with
CO disease than with adult-onset (AO) both at baseline [0·75 (SD 0·173)
vs.  0·64 (SD 0·166),  P  <  0·001] and at the last reported visit
[0·82 (SD 0·167) vs. 0·76 (SD 0·170), P < 0·001]. However, patients
with CO-GHD gained less than AO patients with regard to the total
gain [0·18 (SD 0·488) vs. 0·35 (SD 0·559)] and to the mean gain per
year [0·05 (SD 0·117) vs. 0·09 (SD 0·123)] (Fig. 3).
When controlled for age and gender using multiple regression
analysis, patients with CO disease continued to demonstrate
signiﬁcantly higher QoL-AGHDAutility at baseline and responded to
a lesser extent to GH treatment than patients with AO (P < 0·0001).
Extent of hypopituitarism. The number of additional to GH pitui-
tary hormone deﬁcits showed no signiﬁcant correlation with any of
the QoL-AGHDAutility parameters (Fig.  4). Similarly, patients
with isolated GHD demonstrated equivalent levels of deﬁcit in QoL-
AGHDAutility at baseline and comparable gain during GH treatment
in comparison with patients with multiple pituitary hormone
deﬁciency.
Comorbidities. There was a signiﬁcant impact of reported comorbid-
ities on all QoL parameters. Patients who reported health problems
in addition to GHD (n = 513) had lower QoL-AGHDAutility mean
scores at baseline [0·63  (SD  0·167), P  <  0·001] and at the last
reported visit [0·75  (SD  0·174), P  <  0·001] compared to patients
with no reported comorbidities (n = 381)  [0·71 (SD 0·172)  and
0·81  (SD  0·159), respectively]. At the same time, patients with
comorbidities responded better to GH treatment in terms of QoL-
AGHDAutility [mean 0·36 (SD 0·565) for total gain (P < 0·002) and
0·10 (SD 0·124) for gain/year (P < 0·004)] compared to patients with
no reported comorbidities [0·25  (SD  0·520) and 0·07  (SD  0·119),
respectively].
Discussion
The aim of our study was to investigate clinically assessed QoL in
the context of utilities, an outcome used in cost–utility analysis. The
ﬁrst step was to derive utilities directly from a measure that does not
per se meet pharmacoeconomic requirements but is widely used in
clinical practice. We then evaluated patients’ utilities in relation to
general population values to assess treatment effects, and ﬁnally we
Fig. 2 95% conﬁdence intervals for mean QoL-AGHDAutility at baseline 
(broken line) and at the last reported visit (continuous line) by age group.
Fig. 3 95% conﬁdence intervals for mean QoL-AGHDAutility at baseline and 
during GH replacement therapy in patients with childhood-onset and 
adult-onset GHD.
Fig. 4 95% conﬁdence intervals for mean QoL-AGHDAutility at baseline 
(broken line) and during GH replacement therapy (continuous line) in 
patients by number of pituitary deﬁcits.GH replacement evaluated by a utility-weighted QoL index 127
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analysed different patients’ characteristics to conﬁrm the usefulness
of such outcomes in a clinical setting and in detecting any speciﬁcity
in the patient population with GHD. Additionally, our work was
driven by an emerging practical need for a mutual understanding
between clinicians and health economists with regard to respective
methodology, application and interpretation.
To our knowledge only two previous attempts have been made to
derive utilities from the QoL-AGHDA. The ﬁrst was undertaken by
Dixon et al.,
7 who used a two-step model to link QoL-AGHDA data
through the Nottingham Health Proﬁle (NHP) to utilities based
on an SF-36 algorithm. However, this method might contain a
considerable level of imprecision because of the multiple statistical
imputations. In addition, the values originated from patients,
whereas utility values used for economic evaluation are usually based
on general population values. The second attempt was performed
by our group
8 for a Swedish population. Despite similar methodology,
there are two major differences that are worth discussing, namely the
choice of values and the model applied.
For estimation of any utilities, it is crucial for the ultimate results
that an appropriate set of values for different health states is applied.
Two main issues are involved in the choice of values. First, the way
they are constructed (SG or TTO),
18,19 and second, the reference
population (patients or general public).
20 For the former, we decided
to use values obtained by the TTO method as it has the requisite
basis in theory. For the latter, following the recommendation of the
EuroQoL Group, we chose the general population values originating
from the same country as our patient cohort (E&W).
21 In that way
we hoped to minimize the impact of possible confounders related
to differences in mentality, societal code and culture.
The other methodological issue was the choice of independent
variables entered into the regression analysis (the QoL-AGHDA
summary score, all individual QoL-AGHDA items or selected items
identiﬁed in stepwise forward regression analysis). As the ﬁnal model
yielded an adjusted R
2 of 0·42, whereas in a stepwise forward
regression analysis and in the model with the QoL-AGHDA
summary score the adjusted R
2 assumed the value of 0·40, we decided
to choose the model that ﬁtted our data best.
The novelty of our approach is to apply utilities derived from the
QoL-AGHDA to the patient population and to evaluate QALY
change in a clinical context as a function of treatment response
together with patients’ demographic and clinical characteristics.
Cost–utility analysis based on QALY change is the most widely
recognized method in pharmacoeconomic evaluation, and
QoL-AGHDA was investigated by the National Institute for Health
and Clinical Excellence (NICE) as a potential source of outcome data
for such an evaluation. Nevertheless, the ﬁnal conclusion of
NICE was that there was a lack of evidence to construct a plausible
cost–utility model that would allow cost per QALY to be generated.
22
Our study, despite its observational nature, which is an obvious
limitation, provides a methodology for monitoring QALY changes
over the course of GH replacement in comparison with the age- and
gender-matched population values. Patients showed a profound
QoL deﬁcit before treatment, and signiﬁcant improvement during
follow-up. This pattern is very similar to the pattern of response in
QoL measured by QoL-AGHDA
23 (a dramatic improvement during
the ﬁrst year and a subsequent steady increase during the ensuing
years of treatment). The main difference is that the patients’ utilities,
contrary to the QoL-AGHDA scores, remained different from the
population values during prolonged follow-up. This discrepancy
might be related to the nature of both measures, as QoL-AGHDA
directly records problems linked to GHD, whereas the utility-
weighted index is based on a scoring system that reﬂects a broader
spectrum of health as experienced by the general population. As the
duration of follow-up varied from patient to patient, the change in
QoL-AGHDAutility was calculated as a total gain per follow-up but
also as a gain per year. By doing this, we were able to present results
in a more comprehensive way. It is worth noting that the high
correlation between PGWB scores and QoL-AGHDAutility constitutes
additional evidence for consistency of the methodology.
The last part of our study focused on the impact of demographic
and clinical characteristics including gender, age, primary aetiology,
onset of the disease, extent of hypopituitarism and comorbidities.
Of note, the difference between genders, with women demonstrating
lower pretreatment QoL-AGHDAutility (consistent with the results
from previously published studies demonstrating that female
patients experience worse QoL
24,25), disappeared during the treatment
as the total and mean annual QALY gains were greater in female
patients. This observation, in the light of lower overall responsive-
ness to GH replacement in female patients,
26 further suggests
that response in utilities might comprise additional components
to those directly related to the symptoms of the disease. However, it
should be recognized that gender differences in GH responsiveness
are largely eliminated nowadays when GH dose is titrated against
serum IGF-I rather than being a ﬁxed quantity based on body size.
As expected, QoL expressed as utilities in younger patients was
better (demonstrated by a higher value), which corresponds to many
reports on QoL, both for the population and the patients.
27,28 It is
noteworthy that the QoL gain was not affected by age and that older
patients beneﬁt equally from GH treatment compared to the younger
patients in terms of utilities, supporting previous observations on
the QoL response to GH in older patients with hypopituitarism.
29
Overall, despite some differences at baseline, clinical parameters
did not have an impact on response to treatment; all patients
presented similar total and annual QoL-AGHDAutility gain. The only
exception was patients with CO-GHD and patients with comorbid-
ities. The former responded to GH to a lesser extent. Nevertheless,
it should be remembered that patients with CO-GHD were charac-
terized by higher levels of QoL-AGHDAutility at baseline, so it might
be speculated that their response was driven by the extent of initial
pathology. It has been conﬁrmed that patients with less impairment
in QoL at baseline demonstrate minor response.
30 The same
explanation may apply to the observation that patients who reported
more comorbidities and thus lower QoL-AGHDAutility at baseline
gained more QoL-AGHDAutility during treatment.
Finally, we should highlight the limitations of our study that result
from its observational nature and, by deﬁnition, lack of randomiza-
tion. The main warning applies to the potential selection bias that
could account for some of this striking variation. In the UK, the
major criterion for patient eligibility for GH replacement is impaired
QoL and, as KIMS is a database of patients receiving such treatment,
levels of QoL and thus QoL-AGHDAutility scores may be worse than
in the GH-deﬁcient population at large.128 M. Ko¬towska-Häggström et al.
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At the same time, it should be borne in mind that causal
interpretation of a change observed in any study design other than
double-blind, placebo-controlled, and relating it to a treatment, is
debatable and should be undertaken with considerable caution. This
limitation applies to our study, and we are aware that a clear answer
as to whether or not the observed changes were caused by GH
treatment can only be given by a controlled study. Nevertheless, in
the light of difﬁculties of conducting such a controlled study in
patients with a recognized and approved indication, we believe that
the next best option is an observational study using a large number
of patients and extensive clinical information. In this way we have
attempted to compensate for the lack of placebo-controlled data.
The other limitation of our study relates to the assumption that
GH treatment has no differential impact on mortality. QALYs consist
of two components, quality (utility) and quantity (duration of life),
and both contribute to the ﬁnal value of the index. The increased
mortality rate in hypopituitary patients with untreated GHD has
been proven.
31,32 However, despite promising observations, there is
still no ﬁnal evidence on the beneﬁcial effect of GH replacement on
mortality rates. It should be noted that any ﬁnal QALY estimates
should incorporate treatment effects on patients’ survival together
with the QoL-AGHDAutility gain presented in this paper. Assuming
that GH treatment reverses, at least partly, the increased mortality
associated with hypopituitarism, the total QALY gain should account
for additional life years.
In conclusion, our study reports a new possibility of translating
QoL-AGHDA into utilities. We have shown that this derived QoL-
AGHDAutility index, with its main application to cost–utility analysis,
efﬁciently monitors treatment effects in patients with GHD. The
study conﬁrmed the QoL-AGHDAutility deﬁcit before treatment and
a similar QoL-AGHDAutility gain, despite baseline discrepancies, in
all patients observed after commencement of GH replacement.
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